Shares of Senores Pharmaceuticals Ltd surged 6% to hit the day’s high of Rs 565 on 21st February after its subsidiary signed an agreement to acquire the Abbreviated New Drug Application (ANDA) for Roflumilast 250 mcg and 500 mcg tablets.
Roflumilast is used to reduce the risk of Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients with severe COPD linked to chronic bronchitis and a history of flare-ups.
The market size of Roflumilast in the US stood at $32 million as of MAT June 2024 and grew to $46 million by MAT September 2024, according to the filing.
Swapnil Shah, Managing Director of Senores Pharmaceuticals, stated that acquiring Roflumilast Tablet ANDA is a strategic move to strengthen their speciality distribution portfolio.
Roflumilast’s manufacturing will occur locally at Senores’ US site, ensuring better control over production and distribution.
This acquisition also marks the company’s entry into the chronic bronchitis therapy space, expanding its reach in respiratory care.
The move aligns with Senores’ strategy of identifying niche, under-penetrated generic formulations to address unmet healthcare needs.
At 12:43 PM, the shares of Senores Pharma were trading 4.19% higher at Rs 556.15 on NSE.
Stay Ahead with Senores Pharma. Ask the Analyst.
Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!
